

I. IN THE CLAIMS:

This listing of claims below will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-8. (canceled)

9. (previously presented): An isolated monoclonal antibody against a peptide consisting of amino acid residues 375-580 of GPC 3 as set forth in SEQ ID NO: 4 which is not expressed in normal liver, wherein the antibody has a cytotoxic ADCC or CDC activity in vitro against the cell line HepG2 in the presence of complement or peripheral blood mononuclear cells.

10-24. (canceled)

25. (previously presented): The antibody claimed in claim 9 which is a recombinant antibody.

26. (previously presented): The antibody claimed in claim 25, which is a humanized antibody.

27. (previously presented): The humanized antibody claimed in claim 26, wherein the V region is obtained from an antibody of a mammal except human and the C region is a C region of a human antibody.

28. (previously presented): The humanized antibody claimed in claim 27, wherein the C region of the H chain is selected from the group consisting of C γ 1, C γ 2, C γ 3 and C γ 4.

29. (previously presented): The humanized antibody claimed in claim 27, wherein the C region of the L chain is C κ or C λ .

30. (new) The antibody in claim 9 comprising the CDR1, CDR2 and CDR3 of the H chain variable region as set forth in SEQ ID NO: 10 and the CDR1, CDR2 and CDR3 of the L chain variable region as set forth in SEQ ID NO: 18.

31. (new) The antibody claimed in claim 30 which is a recombinant antibody.

32. (new) The antibody claimed in claim 31, which is a humanized antibody.

33. (new) The humanized antibody claimed in claim 32, wherein the V region is obtained from an antibody of a mammal except human and the C region is a C region of a human antibody.

34. (new) The humanized antibody claimed in claim 32, wherein the C region of the H chain is selected from the group consisting of C γ 1, C γ 2, C γ 3 and C γ 4.

35. (new) The humanized antibody claimed in claim 32, wherein the C region of the L chain is C κ or C λ .

36. (new) The antibody in claim 9 comprising the CDR1, CDR2 and CDR3 of the H chain variable region as set forth in SEQ ID NO: 12 and the CDR1, CDR2 and CDR3 of the L chain variable region as set forth in SEQ ID NO: 20.

37. (new) The antibody claimed in claim 36 which is a recombinant antibody.

38. (new) The antibody claimed in claim 37, which is a humanized antibody.

39. (new) The humanized antibody claimed in claim 38, wherein the V region is obtained from an antibody of a mammal except human and the C region is a C region of a human antibody.

Response dated February 24, 2010

Reply to non-final Office Action of September 1, 2009

40. (new) The humanized antibody claimed in claim 39, wherein the C region of the H chain is selected from the group consisting of C γ 1, C γ 2, C γ 3 and C γ 4.

41. (new) The humanized antibody claimed in claim 39, wherein the C region of the L chain is C κ or C λ .